[PSA recurrence following radical prostatectomy and radiotherapy]

Area of Science:

• Oncology
• Urology
• Biochemistry

Context:

• Prostate cancer recurrence after curative treatments like radical prostatectomy or radiotherapy is a significant clinical challenge.
• Accurate detection and characterization of relapse are crucial for effective patient management.
• Current definitions of biochemical relapse, particularly after radiotherapy, can be complex.

Purpose:

• To clarify the definition and implications of biochemical relapse following localized prostate cancer therapy.
• To highlight the role of PSA kinetics in distinguishing between local and systemic disease recurrence.
• To provide insights into interpreting PSA dynamics for improved clinical decision-making.

Summary:

• Biochemical relapse after prostate cancer treatment is defined by rising Prostate-Specific Antigen (PSA) levels.
• Post-surgery, a PSA of ≥0.4 ng/ml indicates relapse.
• Post-radiotherapy, relapse is defined by three consecutive PSA increases above the post-therapeutic low, based on the 1996 ASTRO consensus.
• PSA kinetics, including PSA doubling time, are vital for differentiating local recurrence from systemic metastasis.
• A short PSA doubling time and early PSA increase suggest systemic disease spread.

Impact:

• Improved understanding of biochemical relapse patterns can lead to earlier detection of metastatic disease.
• Differentiating local vs. systemic relapse aids in tailoring subsequent treatment strategies.
• Enhanced interpretation of PSA kinetics may optimize follow-up protocols and patient outcomes in prostate cancer care.